GB2392910A - 2-Oxopyrimidine derivatives and their use as human leukocyte elastase inhibitors - Google Patents

2-Oxopyrimidine derivatives and their use as human leukocyte elastase inhibitors Download PDF

Info

Publication number
GB2392910A
GB2392910A GB0315870A GB0315870A GB2392910A GB 2392910 A GB2392910 A GB 2392910A GB 0315870 A GB0315870 A GB 0315870A GB 0315870 A GB0315870 A GB 0315870A GB 2392910 A GB2392910 A GB 2392910A
Authority
GB
United Kingdom
Prior art keywords
alkyl
mono
compounds
alkoxycarbonyl
alkoxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
GB0315870A
Other languages
English (en)
Other versions
GB0315870D0 (en
Inventor
Heike Gielen
Volkhart Min-Jian Li
Ulrich Rosentreter
Karl-Heinz Schlemmer
Swen Allerheiligen
Leila Telan
Lars Baerfacker
Joerg Keldenich
Barbara Albrecht
Dirk Meurer
Mary Fitzgerald
Kevin Nash
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer AG
Original Assignee
Bayer AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0220962A external-priority patent/GB0220962D0/en
Application filed by Bayer AG filed Critical Bayer AG
Priority to GB0315870A priority Critical patent/GB2392910A/en
Publication of GB0315870D0 publication Critical patent/GB0315870D0/en
Priority to ARP030103093A priority patent/AR042179A1/es
Priority to NZ538670A priority patent/NZ538670A/en
Priority to JP2004571738A priority patent/JP4708034B2/ja
Priority to KR1020057004110A priority patent/KR20050042190A/ko
Priority to ES03773613T priority patent/ES2414865T3/es
Priority to CA2498051A priority patent/CA2498051C/en
Priority to US10/527,391 priority patent/US7687510B2/en
Priority to MXPA05002644A priority patent/MXPA05002644A/es
Priority to BR0314186-1A priority patent/BR0314186A/pt
Priority to EP03773613.9A priority patent/EP1546113B1/en
Priority to UAA200503292A priority patent/UA82074C2/uk
Priority to PCT/EP2003/009525 priority patent/WO2004024700A1/en
Priority to AU2003282006A priority patent/AU2003282006C1/en
Priority to PL03375647A priority patent/PL375647A1/xx
Priority to UY27965A priority patent/UY27965A1/es
Priority to PE2003000910A priority patent/PE20041078A1/es
Priority to TW092124801A priority patent/TWI314555B/zh
Publication of GB2392910A publication Critical patent/GB2392910A/en
Priority to MA28139A priority patent/MA27431A1/fr
Priority to EC2005005669A priority patent/ECSP055669A/es
Priority to HR20050318A priority patent/HRP20050318A2/xx
Priority to NO20051726A priority patent/NO20051726L/no
Priority to HK06108489.5A priority patent/HK1088304A1/xx
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/20—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D239/22—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
GB0315870A 2002-09-10 2003-07-07 2-Oxopyrimidine derivatives and their use as human leukocyte elastase inhibitors Withdrawn GB2392910A (en)

Priority Applications (23)

Application Number Priority Date Filing Date Title
GB0315870A GB2392910A (en) 2002-09-10 2003-07-07 2-Oxopyrimidine derivatives and their use as human leukocyte elastase inhibitors
ARP030103093A AR042179A1 (es) 2002-09-10 2003-08-27 Derivados de pirimidin-2 ona, procedimiento para sintetizarlos, una composicion, un procedimiento para la preparacion de la composicion y el uso de dichos compuestos para medicamentos
PL03375647A PL375647A1 (en) 2002-09-10 2003-08-28 Pyrimidinone derivatives as therapeutic agents against acute and chronic inflammatory, ischaemic and remodelling processes
JP2004571738A JP4708034B2 (ja) 2002-09-10 2003-08-28 急性および慢性炎症、虚血およびリモデリング過程に対する治療剤としてのピリミジノン誘導体
UAA200503292A UA82074C2 (uk) 2002-09-10 2003-08-28 Похідні піримідинону як терапевтичні агенти проти гострого і хронічного запалення, ішемічних і реконструкційних процесів
AU2003282006A AU2003282006C1 (en) 2002-09-10 2003-08-28 Pyrimidinone derivatives as therapeutic agents against acute and chronic inflammatory ischaemic and remodelling processes
KR1020057004110A KR20050042190A (ko) 2002-09-10 2003-08-28 급성 및 만성 염증성, 허혈성 및 재형성 과정에 대한 치료제로서의 피리미디논 유도체
ES03773613T ES2414865T3 (es) 2002-09-10 2003-08-28 Derivados de pirimidinona como agentes terapéuticos contra procesos inflamatorios agudos y crónicos, isquémicos y de remodelación
CA2498051A CA2498051C (en) 2002-09-10 2003-08-28 Pyrimidinone derivatives as therapeutic agents against acute and chronic inflammatory, ischaemic and remodelling processes
US10/527,391 US7687510B2 (en) 2002-09-10 2003-08-28 Pyrimidinone derivatives as therapeutic agents against acute and chronic inflammatory, ischaemic and remodelling processes
MXPA05002644A MXPA05002644A (es) 2002-09-10 2003-08-28 Derivados de pirimidinona como agentes terapeuticos contra procesos de remodelacion, isquemicos e inflamatorios agudos y cronicos.
BR0314186-1A BR0314186A (pt) 2002-09-10 2003-08-28 Derivados de pirimidinona como agentes terapêuticos contra processos inflamatórios, isquêmicos e remodeladores, agudos e crÈnicos
EP03773613.9A EP1546113B1 (en) 2002-09-10 2003-08-28 Pyrimidinone derivatives as therapeutic agents against acute and chronic inflammatory, ischaemic and remodelling processes
NZ538670A NZ538670A (en) 2002-09-10 2003-08-28 Pyrimidinone derivatives as therapeutic agents against acute and chronic inflammatory, ischaemic and remodelling processes
PCT/EP2003/009525 WO2004024700A1 (en) 2002-09-10 2003-08-28 Pyrimidinone derivatives as therapeutic agents against acute and chronic inflammatory, ischaemic and remodelling processes
UY27965A UY27965A1 (es) 2002-09-10 2003-09-08 Derivados heterocíclicos
TW092124801A TWI314555B (en) 2002-09-10 2003-09-09 Heterocyclic derivatives
PE2003000910A PE20041078A1 (es) 2002-09-10 2003-09-09 Derivados heterociclicos inhibidores de la elastasa leucocitica humana (elh)
MA28139A MA27431A1 (fr) 2002-09-10 2005-03-10 Derives de pyrimidinone utilises comme agents therapeutiques contre des processus inflammatoires ischemiques et de remodelage aigus et chroniques
EC2005005669A ECSP055669A (es) 2002-09-10 2005-03-10 Derivados de pirimidinona como agentes terapéuticos contra procesos de remodelación, isquemicos e inflamatorios agudos y cronicos
HR20050318A HRP20050318A2 (en) 2002-09-10 2005-04-07 Pyrimidinone derivatives as therapeutic agents against acute and chronic inflamatory, ischaemic and remodelling processes
NO20051726A NO20051726L (no) 2002-09-10 2005-04-07 Pyrimidinonderivaer som terapeutiske midler ovenfor akutte og kroniske inflammasjons-, iskemiske og remodeleringsprosesser
HK06108489.5A HK1088304A1 (en) 2002-09-10 2006-07-31 Pyrimidinone derivatives as therapeutic agents against acute and chronic inflammatory, ischaemic and remodelling processes

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0220962A GB0220962D0 (en) 2002-09-10 2002-09-10 Heterocyclic derivatives
GB0315870A GB2392910A (en) 2002-09-10 2003-07-07 2-Oxopyrimidine derivatives and their use as human leukocyte elastase inhibitors

Publications (2)

Publication Number Publication Date
GB0315870D0 GB0315870D0 (en) 2003-08-13
GB2392910A true GB2392910A (en) 2004-03-17

Family

ID=39827677

Family Applications (1)

Application Number Title Priority Date Filing Date
GB0315870A Withdrawn GB2392910A (en) 2002-09-10 2003-07-07 2-Oxopyrimidine derivatives and their use as human leukocyte elastase inhibitors

Country Status (9)

Country Link
JP (1) JP4708034B2 (es)
AR (1) AR042179A1 (es)
EC (1) ECSP055669A (es)
ES (1) ES2414865T3 (es)
GB (1) GB2392910A (es)
HK (1) HK1088304A1 (es)
PE (1) PE20041078A1 (es)
TW (1) TWI314555B (es)
UA (1) UA82074C2 (es)

Cited By (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008030158A1 (en) * 2006-09-04 2008-03-13 Astrazeneca Ab Multimeric heterocyclic compounds useful as neutrophil elastase inhibitors
US7998984B2 (en) 2006-05-08 2011-08-16 Astrazeneca Ab 2-pyridone derivatives for the treatment of disease or condition in which inhibition of neutrophil elastase activity is beneficial
US8063073B2 (en) 2003-09-18 2011-11-22 Astrazeneca Ab 2-pyridone derivatives as neutrophil elastase inhibitors and their use
US8114881B2 (en) 2006-05-08 2012-02-14 Astrazeneca Ab 2-pyrazinone derivatives for the treatment of disease or condition in which inhibition of neutrophil elastase activity is beneficial
US8232296B2 (en) 2009-02-20 2012-07-31 Astrazeneca Ab Salt 628
US8436024B2 (en) 2009-10-02 2013-05-07 Astrazeneca Ab 2-pyridone compounds
US8466284B2 (en) 2007-11-06 2013-06-18 Astra Zeneca Ab Some 2-pyrazinone derivatives and their use as inhibitors of neutrophile elastase
WO2014122160A1 (en) 2013-02-06 2014-08-14 Boehringer Ingelheim International Gmbh Substituted bicyclic dihydropyrimidinones and their use as inhibitors of neutrophil elastase activity
WO2014135414A1 (en) 2013-03-04 2014-09-12 Boehringer Ingelheim International Gmbh Substituted bicyclic dihydropyrimidinones and their use as inhibitors of neutrophil elastase activity
WO2016016366A1 (en) * 2014-07-31 2016-02-04 Boehringer Ingelheim International Gmbh Substituted dihydropyrimidinones and their use as inhibitors of neutrophil elastase activity
US9440930B2 (en) 2014-07-31 2016-09-13 Boehringer Ingelheim International Gmbh Substituted bicyclic dihydropyrimidinones and their use as inhibitors of neutrophil elastase activity
US9458113B2 (en) 2014-07-31 2016-10-04 Boehringer Ingelheim International Gmbh Substituted bicyclic dihydropyrimidinones and their use as inhibitors of neutrophil elastase activity
US9475779B2 (en) 2014-07-31 2016-10-25 Boehringer Ingelheim International Gmbh Substituted bicyclic dihydropyrimidinones and their use as inhibitors of neutrophil elastase activity
US9657015B2 (en) 2014-07-31 2017-05-23 Boehringer Ingelheim International Gmbh Substituted bicyclic dihydropyrimidinones and their use as inhibitors of neutrophil elastase activity
USRE47493E1 (en) 2014-02-20 2019-07-09 Boehringer Ingelheim International Gmbh Substituted bicyclic dihydropyrimidinones and their use as inhibitors of neutrophil elastase activity

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1545450A2 (fr) 2002-09-26 2005-06-29 L'oreal Composition de revetement des fibres keratiniques ayant un extrait sec eleve comprenant un polymere sequence
MXPA03008714A (es) 2002-09-26 2004-09-10 Oreal Polimeros secuenciados y composiciones cosmeticas que comprenden tales polimeros.
FR2860143B1 (fr) 2003-09-26 2008-06-27 Oreal Composition cosmetique comprenant un polymere sequence et une huile siliconee non volatile
CA2557271C (en) * 2004-02-26 2012-08-21 Bayer Healthcare Ag 1,4-diaryl-dihydropyrimidin-2-ones and their use as human neutrophil elastase inhibitors
EP1730121B1 (en) * 2004-02-26 2013-08-07 Bayer Intellectual Property GmbH 1,4-diaryl-dihydropyrimidin-2-ones and their use as human neutrophil elastase inhibitors
FR2904320B1 (fr) 2006-07-27 2008-09-05 Oreal Polymeres sequences, et leur procede de preparation
DE102008022521A1 (de) * 2008-05-07 2009-11-12 Bayer Schering Pharma Aktiengesellschaft 1,4-Diaryl-pyrimidopyridazin-2,5-dione und ihre Verwendung
PL2234985T3 (pl) * 2007-12-20 2012-08-31 Bayer Ip Gmbh 4-(4-cyjano-2-tioarylo)-dihydropirymidynony i ich zastosowanie
ATE540042T1 (de) * 2008-06-09 2012-01-15 Bayer Pharma AG Annelierte 4-(indazolyl)-1,4- dihydropyridinderivate als c-met-mediatoren
DE102009016553A1 (de) * 2009-04-06 2010-10-07 Bayer Schering Pharma Aktiengesellschaft Sulfonamid- und Sulfoximin-substituierte Diaryldihydropyrimidinone und ihre Verwendung

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Journal of Combinatorial Chemistry Vol. 1, 1999, pages 105-112 *

Cited By (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8063073B2 (en) 2003-09-18 2011-11-22 Astrazeneca Ab 2-pyridone derivatives as neutrophil elastase inhibitors and their use
US8501784B2 (en) 2003-09-18 2013-08-06 Astrazeneca Ab 2-pyridone derivatives as neutrophil elastase inhibitors and their use
US7998984B2 (en) 2006-05-08 2011-08-16 Astrazeneca Ab 2-pyridone derivatives for the treatment of disease or condition in which inhibition of neutrophil elastase activity is beneficial
US8114881B2 (en) 2006-05-08 2012-02-14 Astrazeneca Ab 2-pyrazinone derivatives for the treatment of disease or condition in which inhibition of neutrophil elastase activity is beneficial
WO2008030158A1 (en) * 2006-09-04 2008-03-13 Astrazeneca Ab Multimeric heterocyclic compounds useful as neutrophil elastase inhibitors
US8466284B2 (en) 2007-11-06 2013-06-18 Astra Zeneca Ab Some 2-pyrazinone derivatives and their use as inhibitors of neutrophile elastase
US8232296B2 (en) 2009-02-20 2012-07-31 Astrazeneca Ab Salt 628
US8436024B2 (en) 2009-10-02 2013-05-07 Astrazeneca Ab 2-pyridone compounds
WO2014122160A1 (en) 2013-02-06 2014-08-14 Boehringer Ingelheim International Gmbh Substituted bicyclic dihydropyrimidinones and their use as inhibitors of neutrophil elastase activity
US9115093B2 (en) 2013-03-04 2015-08-25 Boehringer Ingelheim International Gmbh Substituted bicyclic dihydropyrimidinones and their use as inhibitors of neutrophil elastase activity
WO2014135414A1 (en) 2013-03-04 2014-09-12 Boehringer Ingelheim International Gmbh Substituted bicyclic dihydropyrimidinones and their use as inhibitors of neutrophil elastase activity
USRE47493E1 (en) 2014-02-20 2019-07-09 Boehringer Ingelheim International Gmbh Substituted bicyclic dihydropyrimidinones and their use as inhibitors of neutrophil elastase activity
WO2016016366A1 (en) * 2014-07-31 2016-02-04 Boehringer Ingelheim International Gmbh Substituted dihydropyrimidinones and their use as inhibitors of neutrophil elastase activity
US9290457B2 (en) 2014-07-31 2016-03-22 Boehringer Ingelheim International Gmbh Substituted dihydropyrimidinones and their use as inhibitors of neutrophil elastase activity
US9440930B2 (en) 2014-07-31 2016-09-13 Boehringer Ingelheim International Gmbh Substituted bicyclic dihydropyrimidinones and their use as inhibitors of neutrophil elastase activity
US9458113B2 (en) 2014-07-31 2016-10-04 Boehringer Ingelheim International Gmbh Substituted bicyclic dihydropyrimidinones and their use as inhibitors of neutrophil elastase activity
US9475779B2 (en) 2014-07-31 2016-10-25 Boehringer Ingelheim International Gmbh Substituted bicyclic dihydropyrimidinones and their use as inhibitors of neutrophil elastase activity
US9657015B2 (en) 2014-07-31 2017-05-23 Boehringer Ingelheim International Gmbh Substituted bicyclic dihydropyrimidinones and their use as inhibitors of neutrophil elastase activity
EP3539952A1 (en) 2014-07-31 2019-09-18 Boehringer Ingelheim International GmbH Substituted bicyclic dihydropyrimidinones and their use as inhibitors of neutrophil elastase activity
EP3604308A1 (en) 2014-07-31 2020-02-05 Boehringer Ingelheim International GmbH Substituted bicyclic dihydropyrimidinones and their use as inhibitors of neutrophil elastase activity

Also Published As

Publication number Publication date
TW200410963A (en) 2004-07-01
PE20041078A1 (es) 2005-02-25
HK1088304A1 (en) 2006-11-03
TWI314555B (en) 2009-09-11
JP4708034B2 (ja) 2011-06-22
UA82074C2 (uk) 2008-03-11
JP2006507355A (ja) 2006-03-02
AR042179A1 (es) 2005-06-15
GB0315870D0 (en) 2003-08-13
ECSP055669A (es) 2005-05-30
ES2414865T3 (es) 2013-07-23

Similar Documents

Publication Publication Date Title
AU2003282006B2 (en) Pyrimidinone derivatives as therapeutic agents against acute and chronic inflammatory ischaemic and remodelling processes
GB2392910A (en) 2-Oxopyrimidine derivatives and their use as human leukocyte elastase inhibitors
CA2498052C (en) Heterocyclic derivatives
CA2496844C (en) Dihydropyridine derivatives for use as human neutrophil elastase inhibitors
EP1720857B1 (en) Dihydropyridinone derivatives
EP1730121B1 (en) 1,4-diaryl-dihydropyrimidin-2-ones and their use as human neutrophil elastase inhibitors
CA2496815C (en) Dihydropyridinone derivatives
EP1723121A1 (en) 1,4-diaryl-dihydropyrimidin-2-ones and their use as human neutrophil elastase inhibitors
JP4708025B2 (ja) ヘテロ環誘導体
RU2376295C2 (ru) Производные пиримидинона и фармацевтическая композиция на их основе, обладающая свойствами ингибитора нейтрофильной эластазы человека

Legal Events

Date Code Title Description
WAP Application withdrawn, taken to be withdrawn or refused ** after publication under section 16(1)